Astrazeneca (AZN) Net Margin Growth (3y) (2012 - 2026)
Astrazeneca (AZN) Net Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Margin Growth (3y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
133.00 |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
1,803.00 |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
1,973.00 |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
544.00 |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-4,534.00 |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-2,543.00 |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
1,355.00 |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-58.00 |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
332.00 |
| 10 |
Astrazeneca |
72.15 Bn |
64.21 Bn |
12.61 Bn |
-407,778.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
-407,778.00 |
| Dec 31, 2025 |
4.51 Mn |
| Sep 30, 2025 |
2.25 Mn |
| Jun 30, 2025 |
5.69 Mn |
| Mar 31, 2025 |
527,140.00 |
| Dec 31, 2024 |
32,966.00 |
| Sep 30, 2024 |
608,391.00 |
| Jun 30, 2024 |
4.76 Mn |
| Mar 31, 2024 |
288,453.00 |
| Dec 31, 2023 |
15,674.00 |
| Sep 30, 2023 |
-45,764.00 |
| Jun 30, 2023 |
51,862.00 |
| Mar 31, 2023 |
626,382.00 |
| Dec 31, 2022 |
88,306.00 |
| Sep 30, 2022 |
81,222.00 |
| Jun 30, 2022 |
-1.20 Mn |
| Mar 31, 2022 |
-212,379.00 |
| Dec 31, 2021 |
-29,305.00 |
| Sep 30, 2021 |
-216,803.00 |
| Jun 30, 2021 |
40,000.00 |
